Odyssey Therapeutics, INC

Odyssey Therapeutics reported Q2 2026 financial results, showcasing positive clinical data for OD-001 and a cash runway extending into late 2028.

Odyssey Therapeutics announced positive Phase 2a data for OD-001 in ulcerative colitis and reported a cash runway into late 2028 following its IPO and private placement.

Odyssey Therapeutics, Inc. announced the closing of a private placement of 1,388,889 shares of common stock at $18.00 per share, concurrent with its initial public offering.

Odyssey Therapeutics, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $38.3 million and cash reserves of $175.7 million, while advancing its lead drug candidates OD-001 and OD-002.

TPG entities reported significant changes in beneficial ownership of Odyssey Therapeutics common stock following the company's initial public offering.

Dimension Capital II, L.P. reported the conversion of preferred stock and a new purchase of common stock in Odyssey Therapeutics, Inc.

SR One Capital Management reports the conversion of preferred stock and warrant exercises in connection with the Odyssey Therapeutics IPO.

Director Jeffrey M. Leiden acquired 5,000 shares of Odyssey Therapeutics, Inc. and converted various preferred holdings into common stock.

Chief Financial Officer Jason Haas acquired 1,000 shares of Odyssey Therapeutics, Inc. common stock at $20 per share.

Director Li Nan disclosed the conversion of preferred stock and participation in the Odyssey Therapeutics IPO.

Odyssey Therapeutics has filed a Rule 462(b) registration statement to increase its common stock offering by 2,599,000 shares.

Odyssey Therapeutics, Inc. has filed an amendment to its S-1 registration statement, detailing plans for an initial public offering of 13,240,000 shares of common stock with an estimated price range of $16.00 to $18.00 per share, aiming for a Nasdaq listing under the symbol ODTX.

Odyssey Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, has filed an S-1 registration statement with the SEC for an initial public offering.

Odyssey Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering, seeking to advance its pipeline of immunomodulatory therapies.

SR One Capital Management reports an 8% beneficial ownership stake in Odyssey Therapeutics following the company's IPO.

TPG GP A, LLC, James G. Coulter, and Jon Winkelried have jointly filed a Schedule 13D, disclosing beneficial ownership of 3,690,146 shares, representing 7.8% of Odyssey Therapeutics, Inc.'s common stock, acquired through a concurrent private placement.

Jeito II S.L.P. and associated entities have filed a Schedule 13D reporting a 7.8% beneficial ownership stake in Odyssey Therapeutics, Inc. following its recent IPO.

FMR LLC and Abigail P. Johnson have reported a 10.2% beneficial ownership stake in Odyssey Therapeutics Inc. common stock.

Lightspeed Venture Partners XV-B (Ignite), L.P. has filed a Schedule 13G reporting a 7.6% beneficial ownership stake in Odyssey Therapeutics, Inc.